Drug intelligence / Profile preview

NX1904

Development stage: Preclinical
Lead developer: NEXTGEN Bioscience
Modality: Small Molecules

Overview

NX1904 is a small molecule therapeutic candidate being developed by the South Korean biotechnology company NEXTGEN Bioscience for the treatment of dry age-related macular degeneration (dry-AMD). Currently in the preclinical stage, the drug is designed to address the progressive vision loss associated with dry-AMD, which is characterized by the atrophy of the retinal pigment epithelium and photoreceptors. While the specific molecular target and mechanism of action have not been publicly disclosed, the program represents a key part of NEXTGEN Bioscience's research into degenerative and age-related diseases.

Beyond the preview

Go deeper on NX1904.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NX1904.

Explore the full profile